Produktname:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
IUPAC Name:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
- CAS：2657617-90-6
- Molekulare Formel：C12H14BF4NO2
- Reinheit：95%+
- Katalognummer：CM1075242
- Molekulargewicht：291.05
| Packungseinheit |
Verfügbarer Vorrat |
Preis($) |
Menge |
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:2657617-90-6
- Molekulare Formel:C12H14BF4NO2
- Schmelzpunkt:-
- SMILES-Code:FC=1C(F)=C(F)C(B2OC(C)(C)C(O2)(C)C)=C(N)C1F
- Dichte:
- Katalognummer:CM1075242
- Molekulargewicht:291.05
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:
Category Infos
- Boronic Acids and Esters
- Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
- Boronic Acid For Sale
- Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Column Infos
- Glecirasib
- On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.
Suche 
+86 21 5895 0110 
